Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 5.2 CHF 1.96% Market Closed
Market Cap: 191.6m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Relative Value

The Relative Value of one MOLN stock under the Base Case scenario is 3.12 CHF. Compared to the current market price of 5.2 CHF, Molecular Partners AG is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOLN Relative Value
Base Case
3.12 CHF
Overvaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
36
Median 3Y
10.2
Median 5Y
21.7
Industry
8.1
Forward
33.1
vs History
vs Industry
13
Median 3Y
-1.6
Median 5Y
-3.2
Industry
23
Forward
-3.2
vs History
vs Industry
14
Median 3Y
-2.2
Median 5Y
-3.2
Industry
23.4
vs History
vs Industry
10
Median 3Y
-2.1
Median 5Y
-3.1
Industry
27.3
vs History
52
vs Industry
57
Median 3Y
1
Median 5Y
1.6
Industry
2.6
vs History
50
vs Industry
70
Median 3Y
-0.1
Median 5Y
6
Industry
8.1
Forward
5.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
20
Median 3Y
-0.2
Median 5Y
-0.9
Industry
4.3
Forward
-0.8
vs History
vs Industry
18
Median 3Y
-0.2
Median 5Y
-0.8
Industry
3.8
Forward
-0.5
vs History
vs Industry
22
Median 3Y
-0.2
Median 5Y
-0.6
Industry
6
vs History
vs Industry
18
Median 3Y
-0.2
Median 5Y
-0.6
Industry
3.8
vs History
52
vs Industry
41
Median 3Y
-2.2
Median 5Y
9.8
Industry
4.8

Multiples Across Competitors

MOLN Competitors Multiples
Molecular Partners AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Molecular Partners AG
SIX:MOLN
191.6m CHF 18.4 -2.8 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
301B USD 5.4 59.2 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 5 38.3 17.8 33.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 4.1 916 10.2 10.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
138B AUD 6 33.9 20.9 26
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 6.4 19 17.5 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
CH
Molecular Partners AG
SIX:MOLN
Average P/E: 213.3
Negative Multiple: -2.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBITDA: 18
Negative Multiple: -0.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBIT: 23.4
Negative Multiple: -0.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top